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Background: 40% of births in the USA are covered by Medicaid and smoking is prevalent among
recipients. The objective of this study was to evaluate the association between levels of Medicaid coverage
for prenatal smoking cessation interventions on quitting during pregnancy and maintaining cessation after
delivery.
Methods: Population based survey study of 7513 post-partum women from 15 states who: participated in
Pregnancy Risk Assessment Monitoring System (PRAMS) during 1998–2000; smoked at the beginning of
their pregnancy; and had Medicaid coverage. Participating states were categorised into three levels of
Medicaid coverage for smoking cessation interventions during prenatal care: extensive (pharmacothera-
pies and counselling); some (pharmacotherapies or counselling); or none. Quit rates among women who
smoked before pregnancy and rates of maintaining cessation were examined.
Results: Higher levels of coverage during prenatal care for smoking cessation interventions were
associated with higher quit rates; 51%, 43%, and 39% of women quit in states with extensive, some, and
no coverage, respectively. Compared to women in states with no coverage, women in states with extensive
coverage had 1.6 times the odds of quitting smoking (odds ratio (OR) 1.58, 95% confidence interval (CI)
1.00 to 2.49). Maintenance of cessation after delivery was associated with extensive levels of Medicaid
coverage; 48% of women maintained cessation in states with extensive coverage compared to 37% of
women in states with no coverage. Compared to women in states with no coverage, women with extensive
coverage had 1.6 times the odds of maintaining cessation (OR 1.63, 95% CI 1.04 to 2.56).
Conclusions: Prenatal Medicaid coverage for both pharmacotherapies and counselling is associated with
higher rates of quitting and continued cessation. This suggests policymakers can promote cessation by
broadening smoking cessation services in Medicaid prenatal coverage.
T
he adverse health and economic impact of smoking
during pregnancy is well established.1–7 Smoking among
pregnant women has implications for the Medicaid
system as it covers prenatal and birth costs for approximately
40% of births in the USA,8 9 and women who receive
Medicaid are 2.5 times more likely to smoke during
pregnancy than women who do not receive Medicaid.10
Effective smoking cessation interventions for use during
prenatal care include counselling (for example, individual,
group, or telephone) and pharmacotherapies (for example,
over the counter and prescription).11–14 Counselling has been
recommended as especially appropriate for pregnant women
due to the controversy of whether or not pharmacotherapies
are safe during pregnancy. Recent work, however, concludes
that the potential benefit of pharmacotherapies outweigh the
risks of continued smoking—especially for those women for
whom counselling is not effective.13 14 Specifically, the
increased cessation rates with the addition of pharmaco-
therapies yield a higher benefit than exposure of the fetus to
carbon monoxide and other toxins if maternal smoking
continues.13
Reimbursement for smoking cessation interventions during
pregnancy is promoted as an important step to address key
provider and system level barriers.15–19 Recommendations for
reimbursement are based on proven effectiveness of smoking
cessation interventions11 19 20 and evidence that they are cost
effective, especially during the prenatal period. Every dollar
spent on smoking cessation interventions for a pregnant smoker
saves $3 in neonatal costs and $6 in long term care costs for
infants with disabilities caused from smoking.21
Although Medicaid is a federally mandated programme,
states have flexibility in their level of coverage beyond the
basic benefit package.15 18 Smoking cessation interventions
are not in the basic benefit package. States may elect to
decrease Medicaid benefits as a short term solution in
response to budget shortfalls or as a way to balance
increasing demand. The challenging fiscal situation in states
requires evaluation of how Medicaid resources can be applied
most effectively to promote health. Although the economic
case to promote coverage of smoking cessation interventions
is a strong one, a limited number of studies have addressed
the effect of incremental increases in coverage.22–24 System
level changes that have increased coverage have had mixed
results, with an increased use of smoking cessation services22
and increased quit rates over 12 month follow up interven-
tion periods23 in two studies, and no change in quit rates in
another study with added coverage for pharmacotherapies.24
None of these studies specifically assessed the influence of
increasing coverage for smoking cessation interventions
among pregnant women.
The purpose of this study was to evaluate the association
between levels of Medicaid coverage for prenatal smoking
cessation interventions on smoking. We used Pregnancy Risk
Assessment Monitoring System (PRAMS) data from 15 states
to assess if: (1) quitting during pregnancy, and (2) main-
taining cessation after delivery was associated with the level




PRAMS provides population based, state specific data for a
variety of maternal behaviours around the time of pregnancy
with linked information from birth certificates.25 PRAMS was
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established in 1987 by the Centers for Disease Control and
Prevention (CDC). In each participating state, 100–200 new
mothers are selected each month from live birth certificates
using a stratified systematic process with over-sampling of
women with specific risks or characteristics (for example, low
birth weight infants, mother’s race). These women receive a
mailed questionnaire between two and six weeks after
delivery. Non-responders receive up to two repeat mailings
and, if necessary, telephone contact. Response rates generally
range from 70–80%. To adjust for over-sampling, the PRAMS
data from each state are weighted so it is representative of all
women giving birth within the selected time period.25
We used data collected in 1998-2000 from 15 states that
participated in PRAMS: Alaska, Alabama, Arkansas,
Colorado, Florida, Illinois, Louisiana, Maine, North
Carolina, New Mexico, New York (excluding New York
City), Oklahoma, South Carolina, Washington, and West
Virginia. Among the 77 981 respondents, 32 272 women
reported that their prenatal care was covered by Medicaid
(41%). We defined Medicaid coverage as a combined variable
including women who had Medicaid before pregnancy,
prenatal care coverage by Medicaid, and prenatal care paid
by a state specific programme (for example, Medipass).
Among the 32 272 women with Medicaid, 20 287 had
complete responses to the questions regarding smoking
before, during, and after pregnancy (63%). The 7513 women
whose prenatal care was paid by Medicaid, who had complete
smoking data, and who reported smoking before pregnancy
are the study population for this analysis. Because this study
used a secondary source for data with no attached identifiers,
the Biomedical Institutional Review Board of the University
of North Carolina at Chapel Hill deemed it exempt from
review.
Study variables
The main outcomes for this study included: (1) quitting
among women who smoked before pregnancy; and (2)
maintaining cessation after delivery among women who quit
smoking during pregnancy. Women were considered to be
smokers if they reported smoking before pregnancy. Women
who reported no smoking at some later point during their
pregnancy were considered to be quitters. Among those who
stopped smoking during pregnancy (quitters), those who
reported no smoking after pregnancy at the PRAMS post-
partum follow up (mean time to follow up 4.1 months) were
considered to have maintained cessation after delivery. In
addition to our two main outcomes, we examined whether
participants reported discussion of smoking information with
prenatal providers. Women were considered to have dis-
cussed smoking cessation if they responded affirmatively to
the PRAMS question: ‘‘During any of your prenatal visits, did
a doctor, nurse or other healthcare worker talk with you
about cigarette smoking?’’
The main independent variable was state level of Medicaid
coverage from smoking cessation services in 1998. Coverage
for the following smoking cessation interventions was
considered: over the counter medications (for example,
nicotine gum, nicotine patch, or any combination), prescrip-
tions (for example, bupropion, spray, inhaler, or any
combination), and counselling (group, individual, telephone,
or any combination). The level of coverage in each state
included in this analysis was obtained from work by
Schauffler, Barker, and Orleans.26 27 We grouped coverage
into three categories of extensive, some, or none. States with
coverage for both counselling (individual, group, or both)
and pharmacotherapies (over the counter, prescription, or
both) were classified as extensive. States with coverage for
any kind of either counselling or pharmocotherapies (over
the counter or prescription) for tobacco dependence were
classified as some. States with no coverage for smoking
cessation interventions were classified as none. We chose to
use the level of Medicaid coverage as reported in 1998 to
assign states into the three levels of coverage because no
state’s coverage was worse in 2000 than 1998, and only four
states had increased coverage in 2000. We assumed that
increased coverage in 2000 would not necessarily have been
adopted immediately at the practice level. Other independent
variables of interest included maternal characteristics (for
example, age, education level, employment, race/ethnicity,
marital status), level of prenatal care, and previous repro-
ductive history (for example, parity, previous preterm birth,
previous low birthweight birth).
Statistical analysis
We used separate bivariate analyses to assess the relationship
of level of state Medicaid coverage (extensive, some, none) to
each of our two outcomes: (1) quit smoking during
pregnancy (quitters), and (2) maintained cessation after
delivery (maintainers). We used a x2 test to examine if the
percentage of women for each outcome differed by level of
Medicaid coverage received. To assess whether any observed
associations between Medicaid coverage and each outcome
might be confounded by other factors, we compared other
characteristics of the women to see if they were unequally
distributed by level of Medicaid coverage. These variables
included maternal age, marital status, race/ethnicity, educa-
tion, parity, previous low birth weight, and previous preterm
birth. We fit separate logistic regression models for each
outcome. Each model included Medicaid coverage and all
potential covariates. Since our definition of coverage was
based on state, and women from the same state may have
other factors contributing to observed differences in out-
comes, we also included state in our analyses as a random
effect. To assess confounding, we compared b estimates for
Medicaid coverage for each outcome with and without
potential confounders. If the b estimates for Medicaid
coverage did not change (. 10%) when covariates were
dropped, these covariates were not included in the final
models. Using the b estimates from the final logistic
regression models, we estimated odds ratios and adjusted
proportions (reported as percentages) by Medicaid coverage
for each outcome. All analyses were performed using the
survey commands from Stata 8.228 for weighted analysis to
adjust for the PRAMS sampling methods. However, there
were two complications with adjusting the analyses for the
sampling scheme stratification variable. First, it was not
possible to control simultaneously for both the sampling
strata and state in the weighted analyses because the strata
were defined uniquely within each state. Second, because our
outcomes were a subset of the entire PRAMS sample
(smokers, and then smokers who quit) some strata were
reduced to only one observation in a stratum. To assess the
effect of the sampling strata on the standard error estimates,
we examined all our analyses adjusting for these strata using
only observations with more than one woman per stratum
and without adjusting for a state effect. The influence on the
standard errors was negligible (that is, differences in the
forth decimal place). However, the state variable had a much
more profound effect on our estimates. Therefore, we
corrected all the analyses for the state effect, as well as the
probability sampling weights (based on the subpopulations
of the sample), but not the sampling strata.
RESULTS
Among the 20 287 women who received Medicaid for
prenatal care, 34% (n = 7513) reported smoking in the
three months before pregnancy and were therefore classified
as smokers and included in the analysis. Among these
Prenatal smoking intervention 31
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women most were between the ages of 20–29 (58%), non-
Hispanic, white (74%), not currently married (64%), and
with an educational level at, or above, graduation from high
school (59%) (table 1). Among smokers, 39% quit during
pregnancy. Among quitters, 39% maintained cessation after
delivery.
In the 15 states in this analysis, eight states (53%) had no
coverage, five states (33%) had some coverage, and two states
(13%) had extensive coverage in 1998. Table 2 provides the
state specific level of Medicaid coverage and proportions of
women from each state who reported smoking before
pregnancy, quitting during pregnancy, and maintaining
cessation after delivery. In 1998, 50% of study women had
no smoking cessation coverage from Medicaid, 46% had some
coverage, and 4% had extensive coverage. A majority (89%)
of women (smokers and non-smokers) reported a prenatal
discussion about smoking with their health care provider.
After adjusting for covariates, higher levels of Medicaid
coverage in 1998 were associated with an increased like-
lihood of quitting (table 3). Specifically, 51% of women in
states with extensive coverage quit smoking during preg-
nancy compared to 43% of women in states with some
coverage and 39% of women in states with no coverage.
Compared to women in states with no coverage, women in
states with extensive coverage had 1.6 times the odds of
quitting smoking (odd ratio (OR) 1.58, 95% confidence
interval (CI) 1.00 to 2.49); women in states with some
coverage had 1.2 times the odds of quitting (OR 1.18, 95% CI
1.03 to 1.34). Maintenance of cessation after delivery was
associated with extensive levels of Medicaid coverage
(table 3). Specifically, 48% of women in states with extensive
coverage maintained cessation after delivery, while 37% of
women who quit smoking during pregnancy in states with no
or some coverage maintained cessation. Compared to women
in states with no coverage, women with extensive coverage
had 1.6 times the odds of maintaining cessation (OR 1.63,
95% CI 1.04 to 2.56). The odds of maintaining cessation were
similar for women in states with some and no coverage (OR
1.02, 95% CI 0.89 to 1.18).
DISCUSSION
This work shows the inclusion of prenatal Medicaid coverage
for both pharmacotherapies and counselling is associated
with higher rates of quitting during pregnancy and main-
taining cessation after delivery. Combined with the effective-
ness and cost effectiveness of smoking cessation
interventions19 and previous recommendations to provide
extensive smoking cessation coverage,11 14 19 29 this work
supports increasing resource allocation to prenatal Medicaid
smoking cessation interventions.
For increased reimbursement strategies to be successful,
other supporting components are needed to expand the
capacity to deliver smoking cessation interventions.18 A
Table 2 State profiles of level of Medicaid coverage, smokers (before pregnancy),













Alaska None 47 40 45
Alabama None 32 37 41
Arkansas None 42 29 43
Colorado Some 40 42 44
Florida Some 28 39 37
Illinois None 31 39 37
Louisiana Some 27 40 38
Maine Extensive 57 36 62
North Carolina Some 35 40 38
New Mexico Extensive 33 54 44
New York None 43 40 32
Oklahoma Some 46 46 43
South Carolina None 31 40 35
Washington None 31 38 43
West Virginia None 56 32 44
Average 34 39 39
*Percentages weighted for sampling scheme.
Table 3 Relationship between level of Medicaid
coverage in 1998 and quitting and maintaining cessation,




(among quitters) (n = 2829)
%* Odds ratio (95% CI)* % Odds Ratio (95% CI)
Coverage
Extensive 51 1.58 (1.00 to 2.49) 48 1.63 (1.04 to 2.56)
Some 43 1.18 (1.03 to 1.34) 37 1.02 (0.89 to 1.18)
None 39 1.00 37 1.00
*Adjusted for maternal age, marital status, race, previous preterm birth.
Adjusted for marital status, previous preterm birth.
Table 1 Sociodemographic characteristics of
study women, weighted to reflect PRAMS















Less than 12 years 41
HS graduate or GED 44




GED, General Educational Development; HS, high school.
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suggested model for comprehensively addressing this goal for
pregnant women includes: support from top leadership in the
health organisation; clinical information systems to track
individual patient information; ongoing training of providers
and staff; the assignment of specific staff to provide smoking
cessation counselling; innovative support systems for smo-
kers trying to quit; and community support.18
Increasing each state’s capacity to deliver smoking cessa-
tion interventions needs to address the barriers that exist at
the level of the prenatal provider.11 14 30 Something as
essential as a provider’s awareness of changes in reimburse-
ment for coverage needs to be considered. An evaluation of
physician knowledge about Medicaid coverage for smoking
cessation in two states with extensive coverage (included
counselling and pharmacotherapy) found that only 58% of
providers were aware of coverage for pharmacotherapy and
only 23% were aware of coverage for counselling.31 Clearly,
providers who are unaware of improved coverage for
smoking cessation interventions will be less likely to change
their practice and incorporate such procedures.
The limitations of this study include the reliance on
retrospective and self reported smoking descriptions which
may result in reporting bias as individuals, especially during
pregnancy, may underreport the amount of smoking or report
cessation when they continue to smoke.32–34 In addition,
several considerations limit our ability to determine causality
in this project. There may have been state level factors other
than the level of Medicaid reimbursement that affected
whether pregnant women quit, or maintained cessation. For
example, both Maine and New Mexico (states with extensive
coverage) may have had unique characteristics such as an
emphasis on smoke-free environments, enhanced prenatal
provider education, or increased stigma for reporting smok-
ing during pregnancy. The determination of direct causality is
also limited by the lack of detail offered from the PRAMS
question regarding what specific components of an interven-
tion that a participant received. Prenatal care providers may
not have known the level of Medicaid reimbursement and
therefore their practice may not have been affected by the
reimbursement level. Our use of the level of coverage in 1998
was selected as a way to allow time for state level change in
the Medicaid reimbursement to filter down to the practice
level.
In conclusion, this work provides timely evidence regard-
ing the importance of continuing to increase Medicaid
reimbursement for smoking cessation interventions as states
struggle with critical funding decisions.35 Without improved
resource allocation to provide coverage to pregnant women
receiving Medicaid, we are missing an opportunity to affect
positively the short and long term maternal and child health
status to the women who begin their pregnancy as a smoker.
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Tobacco advertising on mini-motors
C
omprehensive smoke-free legislation has been in place
in New Zealand for over 15 years and for much of that
time advertising of tobacco products or the use of
tobacco trademarks on goods other than tobacco products
has been banned. Despite this legislation, retail products
occasionally appear that clearly breach the legislation. The
most recent example of such products was found in Dunedin
in 2005. In this example, mini-bikes (also referred to as
pocket bikes) displayed branding for Lucky Strike and Camel
cigarettes. Although it is not clear if British American
Tobacco or RJ Reynolds were aware of the use of their
product trademark, the trademarks closely resembled those
used by the manufacturers. These motorised bikes were
manufactured in China and appear to appeal to young males
aged 12–13 years and older. The bikes were withdrawn from
sale when the retailer was notified of the violation of
legislation.
Even in a country with legislation that explicitly removes
tobacco brand images and advertising there remains a need
to be vigilant for tobacco product promotion, whether this
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